Strong clinical data supporting Alluzience (abobotulinumtoxinA, ABO), the first liquid, ready-to-use neuromodulator as an effective and well-tolerated treatment for glabellar (frown) lines, with a rapid onset and long duration of action of up to six months
Data confirming that Dysport was consistently efficacious for the treatment of frown lines, was well tolerated and had a fast onset of effect across three trials with high patient satisfaction reported up to 6 months after injection in phase III trials
Phase IV data confirming the effectiveness and natural-looking effects with the Restylane range of hyaluronic acid fillers, with all patients achieving the aim of their treatment, whether it was projection or contouring/volumization with results that were natural-looking with high subject satisfaction
Presentation of the latest extension study for Sculptra, the original poly-L-lactic acid (PLLA) which demonstrated it to be well-tolerated and with long-lasting effectiveness until week 96 using reconstituted 8mL dilution.
ZUG, Switzerland--(BUSINESS WIRE)--Galderma will present a range of new clinical data and analyses across its portfolio during nine poster sessions and two symposia at the upcoming International Master Course on Aging Science (IMCAS) World Congress 2022 in Paris from June 3-5, 2022.
|
“At Galderma, we are committed to advancing dermatology for every skin story. The extensive series of oral and poster presentations with new data from across our portfolio demonstrates our drive for innovation across the industry. We will also be hosting two symposia with leading physicians, reinforcing our partnership with the aesthetics community as we present work completed with them to deliver holistic individualized treatments (HITs) for patients and the science and clinical experience behind our latest innovation Alluzience, the first ready-to-use neuromodulator” Flemming Ørnskov, M.D., MPH Chief Executive Officer Galderma |
